Injectable Drug Delivery Market by Type (Device, Formulation), Therapeutic (Cancer), Usage Pattern (Immunization), Administration (Skin, Musculoskeletal), Distribution Channel (Hospital), Patient Care Setting (Hospital, Home Care) - Forecast to 2021
The global injectable drug delivery market, in terms of value, is projected to reach USD 624.50 billion by 2021 from USD 362.38 billion in 2016, at a CAGR of 11.5% during the forecast period.
The increase in the use of biologics, the increase in the prevalence of chronic diseases, the increasing occurrence of needlestick injuries, and the benefits of injections (convenience, ease of use, and reduced pain) have driven the growth of the injectable drug delivery market. These factors have increased the demand for devices such as safety syringes, prefilled syringes, and autoinjectors. However, the growing use of alternative delivery methods, safety concerns, and risk of transmission of blood-borne infections may hinder the growth of the market.
The injectable drug delivery is segmented based on type, formulation packaging, therapeutic application, usage pattern, site of administration, distribution channel, facility of use, and regions. Injectable drug delivery market by distribution channel is further segmented into hospitals and pharma stores. Hospitals are expected to account for a large share in this market, as hospitals provide injectables for the inpatients as well as to the outpatients, owing to which there is maximum sale of injectable formulations and devices through the hospitals. In addition, it provides pharmacy care for inpatients as well as patients from other clinics, ambulatory centers, patients discharged from healthcare facilities, and those receiving home care.
The Injectable drug delivery market by facility of use is segmented into hospitals and clinics, home care settings, and other facilities of use. The hospitals and clinics segment is expected to account for the largest share of the market, primarily due to the rising incidence of chronic diseases such as diabetes and cancer which require a large number of injectables for their treatment.
Asia is expected to be the fastest growing region in the market from 2016 to 2021 due to the rising incidence of chronic and autoimmune diseases, the rising aging population, and the high penetration of self-injection techniques & technologies in countries such as China, Japan, and India.
Prominent players in the injectable drug delivery market include Becton, Dickinson and Company (U.S.), Baxter International (U.S.), Pfizer (U.S.), Gerresheimer AG (Germany), Schott AG (Germany), Eli Lilly and Company (U.S.), and Terumo Corporation (Japan).
The report defines, describes, and forecasts the injectable drug delivery market on the basis of type, formulation packaging, therapeutic application, usage pattern, site of administration, distribution channel, and facility of use. It provides detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, challenges). The study tracks and analyzes competitive developments such as joint ventures, mergers & acquisitions, product developments, and expansions in the injectable drug delivery market across four main regions, namely, North America, Asia, Europe, and the Rest of the World (RoW).
Reasons to buy the report:
The report provides clients market size information on various segments of the injectable drug delivery market. This report also provides access to the quantitative data on the market. This report covers –
Current and forecast assessment of the injectable drug delivery market
Country-wise assessment of each of the segments
Global market share analysis for major segments of the injectable drug delivery market
Adoption Trends of injectable drug delivery for major geographic markets
Five-year coverage of strategic developments of top players in the injectable drug delivery market
Product Portfolio mapping of leading players in the injectable drug delivery market